The GV and EMBL Ventures-backed immunotherapy developer floated in an underpriced offering and received $20m in a private placement from NEA.

The urologic and gastrointestinal disorder treatment developer has raised another $20m in its Novo and Takeda-backed series A round.

The Cambridge spinout is commercialising research into better techniques for extracting quality stem cells, having raised a reported $464,000 in seed funding.

Novo and Sanofi have backed a series A round for Inozyme Pharma, which is developing treatments for rare diseases affecting infants based on research at Yale.

The medical imaging technology developer raised cash in a series B round backed by GE, Varian, Fosun, Northwell Health and NewYork-Presbyterian.

Saarland-founded AkknaTek is developing an imaging aid for cataract surgery to improve the precision of intraocular lenses implanted during the procedure.

Fosun Pharma and Ping An were among the investors that are providing $30m for MitrAssist in a two-tranche round.

The Bluefield Innovations vehicle will back early-stage Johns Hopkins projects over five years with a view to eventually spinning out or licensing promising ideas.